Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Results from two randomized, placebo-controlled, phase III trials

K. A. Papp*, M. A. Menter, M. Abe, B. Elewski, S. R. Feldman, A. B. Gottlieb, R. Langley, T. Luger, D. Thaci, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk

*Corresponding author for this work
86 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Results from two randomized, placebo-controlled, phase III trials'. Together they form a unique fingerprint.

Medicine & Life Sciences